Alembic Pharma gets USFDA approval to market generic cancer drug ...Middle East

Alembic Pharmaceuticals on Wednesday said it has received approval from the US health regulator to market a generic breast cancer drug. The company has received approval from the US Food & Drug Administration (USFDA) to market Docetaxel Injection in multiple dose vials, the drug maker said in a statement. The company's approved product is therapeutically equivalent to Hospira Inc's drug. Docetaxel Injections are indicated for breast cancer, non-small cell lung cancer, castration-resistant prostate cancer, gastric adenocarcinoma and squamous cell carcinoma of head and neck. According to IQVIA data, Docetaxel injection has an estimated market size of USD 11 million in the US market. Shares of

Read More Details
Finally We wish PressBee provided you with enough information of ( Alembic Pharma gets USFDA approval to market generic cancer drug )

Also on site :

• G42 a Mistral AI sa spájajú so zámerom budovať platformy a infraštruktúry umelej inteligencie novej generácie
• Companies turn to AI to navigate Trump tariff turbulence
• Your new sofa could be the first sign tariff inflation is hitting home